|
[1]SAKAI R, TANAKA M, NANK T, et al.Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients rcceiving anticytokine therapy with different target molecules[J].Ann Rheum Dis, 2012, 71 (11) :1820-1826.
|
|
[2]LIU J, ZHU CH.Statistical analysis for adverse reactions induced by etanercept[J].Clin Med Eng, 2012, 19 (12) :2258-2259. (in Chinese) 刘娟, 朱灿辉.益赛普致不良反应统计分析[J].临床医学工程, 2012, 19 (12) :2258-2259.
|
|
[3]ZHANG Q, HUANG SJ, LUO T, et al.A case of mild liver injury induced by recombinant human tumor necrosis factor receptor-antibody fusion protein for injection[J].Pharm Care Res, 2017, 17 (6) :460-469. (in Chinese) 张琴, 黄姗剑, 骆婷, 等.注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白致轻度肝损伤一例[J].药学服务与研究, 2017, 17 (6) :460-469.
|
|
[4]Drug-induced Liver Disease Study Group, Chinese Society of Hepatology, Chinese Medical Association.Guidelines for the management of drug-induced liver injury[J].J Clin Hepatol, 2015, 31 (11) :1752-1769. (in Chinese) 中华医学会肝病学分会药物性肝病学组.药物性肝损伤诊治指南[J].临床肝胆病杂志, 2015, 31 (11) :1752-1769.
|
|
[5]YU YC, FAN Y, CHEN CW.Diagnosis and treatment of druginduced liver injury[J].J Clin Hepatol, 2018, 31 (6) :1160-1165. (in Chinese) 于乐成, 范晔, 陈成伟.药物性肝损伤的诊断和治疗[J].临床肝胆病杂志, 2018, 31 (6) :1160-1165.
|
|
[6]KARCZMAREK-BOROWSKA B, SALEK-ZAN'A.Hepatotoxicity of molecular targeted therapy[J].Contemp Oncol (Pozn) , 2015, 19 (2) :87-92.
|
|
[7]FONTANA RJ.Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives[J].Gastroenterology, 2014, 146 (4) :914-928.
|
|
[8]FISHER K, VUPPALANCHI R, SAXENA R.Drug-induced liver injury[J].Arch Pathol Lab Med, 2015, 139 (7) :876-887.
|
|
[9]KLEINER DE, CHALASANI NP, LEE WM, et al.Hepatic histological findings in suspected drug-induced liver injury:Systematic evaluation and clinical associations[J].Hepatology, 2014, 59 (2) :661-670.
|
|
[10]YU YC, MAO YM, CHEN CW, et al.CSH guideline for the diagnosis and treatment of drug-induced liver injury[J].Hepatol Int, 2017, 11 (3) :221-241.
|
DownLoad: